Mode
Text Size
Log in / Sign up

Visual biofeedback shows faster early progress than motor-based therapy for children with residual speech sound disorder

Visual biofeedback shows faster early progress than motor-based therapy for children with residual s…
Photo by Navy Medicine / Unsplash
Key Takeaway
Consider visual biofeedback for potentially faster early progress in children with residual speech sound disorder affecting /ɹ/.

This randomized controlled trial compared visual biofeedback treatment to motor-based treatment in 108 children aged 9-15 years with residual speech sound disorder affecting American English /ɹ/. The biofeedback intervention was subdivided into ultrasound and visual-acoustic types, while the comparator was motor-based treatment consistent with current best practices in speech therapy. The primary outcome was rate of progress in the first three sessions, quantified by an acoustic measure of distance between the second and third formants.

The study found a statistically significant interaction between treatment type and session, with the rate of progress significantly faster in the biofeedback condition compared to motor-based treatment. However, no statistically significant difference was observed between the ultrasound and visual-acoustic biofeedback types. Secondary outcomes included generalization learning after treatment completion, but results for this endpoint were not reported in the available data.

Safety and tolerability data were not reported. The study's limitations include that previous research in this area has had inconclusive results due to study design limitations and small sample sizes. While this trial with 108 participants provides more robust evidence, the findings should be interpreted cautiously as they primarily address early treatment progress rather than long-term outcomes or generalization. The results support previous small-scale research suggesting biofeedback can help children with residual speech sound disorder acquire American English /ɹ/, but do not establish superiority over standard care for all treatment outcomes.

Study Details

Study typeRct
EvidenceLevel 2
Follow-up180.0 mo
PublishedApr 2026
View Original Abstract ↓
PURPOSE: Residual speech sound disorder (RSSD) is a high-prevalence condition that can limit children's academic and social participation, with negative consequences for overall well-being. Previous studies have described visual biofeedback as a promising option for RSSD, but results have been inconclusive due to study design limitations and small sample sizes. METHOD: In a preregistered randomized controlled trial, 108 children aged 9-15 years with RSSD affecting American English /ɹ/ were randomly assigned to receive treatment incorporating visual biofeedback (subdivided into ultrasound and visual-acoustic types) or a comparison condition of motor-based treatment consistent with current best practices in speech therapy. An acoustic measure (the distance between the second and third formants, which is smaller in perceptually accurate /ɹ/) was used to quantify progress in the first three sessions of treatment in participants' assigned condition. The focus on the early stages of treatment was grounded in principles of motor learning: As a type of knowledge of performance feedback, biofeedback is expected to have its greatest impact during initial acquisition of a new speech-motor plan. RESULTS: A linear mixed-effects regression model revealed a statistically significant interaction between treatment type and session: While both groups made progress over time, the rate of progress was significantly faster in the biofeedback condition compared to motor-based treatment. No statistically significant difference was observed between the ultrasound and visual-acoustic types of biofeedback. DISCUSSION: This large-scale randomized controlled trial supports previous small-scale research in finding that biofeedback can help children with RSSD acquire American English /ɹ/. A companion study will compare participants' generalization learning after the end of all treatment. SUPPLEMENTAL MATERIAL: https://doi.org/10.23641/asha.29971501.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.